Chairs: Nicola Ciavarella, David Lillicrap
08.30 Will severe hemophilia become more common in the future? The effects of population demographics on the prevalence of hemophilia
Manuel Carcao, Canada
09.00 Determinants of factor VIII inhibitor risk. Is von Willebrand factor a key factor?
David Lillicrap, Canada
09.30 Endocytosis of factor factor VIII by antigen-presenting cells: roles of von Willebrand factor and complement
Sebastien Lacroix-Desmazes, France
10.00 Paradigm shift of the treatment of hemophilia A by factor VIII mimicking bispecific antibody
Midori Shima, Japan
10.30 The challenges of innovative therapeutic interventions in hemophilia
Louis M. Aledort, USA
11.00 Break & Poster Session
SCIENTIFIC SESSION 2 – Von Willebrand disease
Chairs: Giancarlo Castaman, Augusto B. Federici
11.30 Von Willebrand factor regulation of blood vessel formation and function
Anna Maria Randi, UK
12.00 Gastrointestinal bleeding in von Willebrand disease: an unresolved problem
Giancarlo Castaman, Italy
12.30 The potential use of nanobodies In the treatment of von Willebrand disease (VWD) and hemophilia
Peter Lenting, France
13.00 Lunch & Poster Session
Chairs: Pier Mannuccio Mannucci, Massimo Franchini
14.30 Desmopressin (DDVAP): 40 years after.
15.30 Satellite Symponsium Sponsored by SOBI
16.30 Break & Poster Session
SCIENTIFIC SESSION 3 – Thrombotic microangiopathies
Chairs: Flora Peyvandi, Johana Kremer Hovinga
17.00 Mechanism of thrombotic microangiopathy: lesson from zebrafish to men
X. Long Zheng, USA 
17.30 Differential diagnosis of thrombotic microangiopathies
Jeffrey C. Laurence, USA 
18.00 Immune repertoire in acquired TTP
Johana Kramer Hovinga, Switzerland